KPV: The NF-kB Inhibiting Tripeptide in Anti-Inflammatory Research

Blog / Healing & Recovery / KPV

KPV: The NF-κB Inhibiting Tripeptide in Anti-Inflammatory Research

The Quiet One · Healing & Recovery

KPV (Lys-Pro-Val) is a three-amino acid tripeptide derived from the C-terminal region of alpha-MSH (positions 11–13). Despite its tiny size, it has drawn significant research attention for its ability to directly inhibit NF-κB — the body’s master inflammatory transcription factor.

What Is KPV?

KPV stands for Lysine-Proline-Valine. It is the three-amino acid C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), a 13-amino acid peptide derived from POMC. While alpha-MSH exerts its anti-inflammatory effects through melanocortin receptors (MC1-R through MC5-R), KPV operates through an entirely different mechanism: direct NF-κB pathway inhibition.

This receptor-independent activity means KPV avoids melanocortin-related side effects like pigmentation changes while retaining potent anti-inflammatory signaling.

NF-κB Inhibition Mechanism

NF-κB is a transcription factor that controls the expression of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. In chronic inflammation — particularly inflammatory bowel disease — NF-κB is persistently activated, driving tissue damage.

KPV suppresses NF-κB by inhibiting IKK (IκB kinase) activity, preventing degradation of the IκBα inhibitor protein, and blocking nuclear translocation of the p65 subunit. This shuts down the transcriptional machinery that produces inflammatory cytokines.

Gut-Specific Absorption via PepT1

At only three amino acids, KPV is small enough to be transported by the PepT1 (H+/peptide cotransporter 1) system on intestinal epithelial cells. This transporter normally absorbs dietary di- and tripeptides. Because KPV is a natural substrate, it can be absorbed intact into the gut lining — where it exerts its anti-inflammatory effects directly at the mucosal level.

Preclinical IBD and Colitis Research

In DSS-induced colitis models, oral KPV significantly reduced disease activity scores, body weight loss, and inflammatory cell infiltration. In TNBS colitis (Crohn’s-like), KPV reduced colonic TNF-α and IL-1β production — with results comparable to or exceeding the full alpha-MSH molecule.

KPV has also shown intrinsic antimicrobial activity against gram-positive and gram-negative bacteria, likely through its cationic lysine residue disrupting bacterial membranes.

KPV vs. Full Alpha-MSH

Safety and Limitations

Preclinical safety data is favorable: no melanocortin receptor activation, no organ toxicity at supratherapeutic doses, and derivation from an endogenous hormone fragment. However, no human clinical trials have been published. Optimal dosing, long-term safety, and efficacy in humans remain undetermined.

Sources: Getting et al. PMID: 11282135; Peptide Journal KPV summary.

Disclaimer: This article is for informational and research purposes only. KPV is sold as a research peptide and is not FDA-approved for human therapeutic use.